Interestingly, the studies discussed in this review also showed that SLC7A11 expression can be downregulated by natural (agrimonolide, fructose and eriodictyol) and synthetic (olaparib, lidocaine and erastin) compounds (see Table 1), suggesting a potential use of these compounds in ovarian cancer treatment. Here, SLC7A11 is linked to ovarian cancer.